Asterias Biotherapeutics Inc

Asterias Biotherapeutics — Investor Presentation (April 2016)

28 slides from Asterias Biotherapeutics's investor presentation, Apr 5, 2016

  1. Slide 1: Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Oncology and Neurology

    Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Oncology and Neurology Asterias Biotherapeutics NYSE: ASTApril 4, 2016

  2. Slide 2: Forward-Looking Statements

    Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute

  3. Slide 3: Clinical-Stage Programs and Corporate Highlights

    3 Technology Platforms Non-Dilutive Funding via Partnerships AST-VAC1 – Planning P3 trial in acute myeloid leukemia (AML)AST-VAC2 – Planning P1/2a trial in non-small cell lung cancer (NSCLC)AST-OPC1 – Ongoing Phase 1/2a trial in spinal cord injury (SCI) California Institute of Regenerative Medicine

  4. Slide 4: Two Clinical-Stage Regenerative Platform Technologies

    Cancer ImmunotherapyStimulates patients’ immune system to attack telomerase, a protein that is expressed in over 95% of cancersAST-VAC1: Patient-specific (autologous) based on a patient’s own cells AST-VAC2: Non-patient specific (allogeneic) based on pluripotent stem cellsPluripotent Stem Cells Scal

  5. Slide 5: Development Pipeline

    5 PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS AST-VAC1Leukemia (AML) Autologous Planning Phase 3 start late 2017 AST-VAC2Lung Cancer Allogeneic Planning Phase 1/2astart Q1 2017 Potential in multiple cancer types/stages as well as combination therapy AST-OPC1Spinal Cord Injury (sub acute) Phas

  6. Slide 6: AST-VAC1: Acute Myelogenous Leukemia (AML)

    Patient-specific (autologous)Acute Myelogenous Leukemia (AML)Planning phase 3 clinical trial start for late 2017 AST-VAC1

  7. Slide 7: AST-VAC1: Activating a patient's immune system to target telomerase

    AST-VAC1: Activating a patients’ immune system to recognize and target telomerase, a universal cancer antigen 7 Dendritic Cells: Potent Antigen Presenting Cells AST-VAC1 is an autologous cell-based immunotherapy that enables a patient’s own dendritic cells (DCs) to stimulate an immune response to te

  8. Slide 8: VAC technology designed to overcome limitations of first-generation DC therapies

    8 Asterias’ VAC technology is designed to overcome the limitations of older, first-generation DC therapies LAMP sequenceEnhance immune response to telomerase mRNA loadingBroaden antigen presentation Intradermal deliveryAccess lymph nodes Mature DCsMaximize T-cell stimulation ManufacturingScalable fo

  9. Slide 9: Relapse-free survival in AML patients >60 years of age

    9 Relapse-free survival (RFS) in AML patients >60 years of age1 Only 10-20% RFS at 4 years (1) Rollig J Clin Onc 2011; (2) Decision Resources There is a significant unmet need for better therapies to extend remission in AML patients (especially >60 years) “The incidence of AML continues to increase

  10. Slide 10: Two step AML treatment paradigm

    10 Two step AML treatment paradigm AST-VAC1: potential to safely extend AML remission Step 1: InductionChemotherapy to get patients to complete remissionRarely used in older patients due to low tolerability and high rates of relapse Step 2: ConsolidationChemotherapy and/or HCT to maintain remission

  11. Slide 11: AST-VAC1: favorable safety profile

    11 AST-VAC1: favorable safety profile, with only 1 out of 41 patients exhibiting a possibly related SAE AST-VAC1 has demonstrated a favorable safety profile across 41 patients in Phase 1 and Phase 2 trials Two clinical studies have demonstrated safety of AST-VAC1 Patients receiving VAC1 Safety Resul

  12. Slide 12: AST-VAC1 Phase 2 relapse-free survival results

    12 57% 10-20% >60 years old 20-40% 58% All patients Relapse free survival at 52 months(% of patients) Historical2 AST-VAC11 (1) Mayer NEJM 1994; Rollig, J Clin Onc 2011(2) VAC1 P2 results, presented at ASCO, May 2015; manuscript submitted AST-VAC1 Phase 2 highlightsMay extend relapse-free survival i

  13. Slide 13: Successful End-of-Phase 2 FDA meeting

    Successful End-of-Phase 2 FDA meetingPaves way for a potential accelerated development pathway FDA meeting recapFDA indicated general agreement with Asterias’ plan of a single Phase 3, placebo controlled trial to support an accelerated pathway and BLA filingPositive results could be basis for accele

  14. Slide 14: AST-VAC1 clinical plan for accelerated approval

    Phase 4 Confirmatory Trial 14 Single Phase 3 Trial in 60 years+ /high-risk AML Manufacturing process development, trial planning and SPA request AST-VAC1 clinical plan developed for accelerated approval Potential for accelerated approval if Phase 2 results confirmed in Phase 3 study:AST-VAC1 could b

  15. Slide 15: AST-VAC1 targets need for alternative to consolidation therapy in AML

    15 AST-VAC1 targets a significant need for an alternative to consolidation therapy in AML in patients >60 years, high risk ~19,000 new AML cases diagnosed and ~10,500 deaths from AML in US annually (2014 estimate)AML incidence increases markedly after 60 and older patients do not tolerate AML therap

  16. Slide 16: AST-VAC2: Non-small cell lung cancer (NSCLC)

    Non-patient specific (allogeneic), “ready-for-use”Non-small cell lung cancer (NSCLC)Development partnership with Cancer Research UKPlanning phase 1/2a clinical trial to start Q1 2017 AST-VAC2

  17. Slide 17: AST-VAC2: potential ready for use non-patient specific product

    17 Centralized Production Facility Point Of Care Distributed Frozen Inventory AST-VAC2: potential ‘ready for use’ non-patient specific product AST-VAC2 cells are mature allogeneic dendritic cells that have been transfected with hTERT and LAMP(4,5) like AST-VAC1With AST-VAC2 there is no need to produ

  18. Slide 18: AST-VAC2: partnered with CRUK for P1/2 trial

    18 Partnership with Cancer Research UK (CRUK) pays full cost of GMP manufacturing, regulatory filing, and Phase 1/2a studyNon-small cell lung cancer (NSCLC) selected as lead indication given high unmet medical need and responsiveness to immune therapiesCRUK partnership saves Asterias an estimated $2

  19. Slide 19: AST-VAC2: large commercial potential in NSCLC

    19 AST-VAC2: large commercial potential; targeting a very large unmet need in NSCLC, one of the deadliest cancer types NSCLC: large patient population, high mortality rate (1) NCI SEER Cancer Statistics Review; (2) American Lung Society Not Staged3% Lung cancer: the most common type of cancer2Estima

  20. Slide 20: AST-OPC1: Spinal Cord Injury

    Pluripotent stem cell platformSignificant grant funding from California Institute of Regenerative Medicine (CIRM)Phase 1/2a clinical trial in spinal cord injury in progress AST-OPC1

  21. Slide 21: AST-OPC1 – Addressing the complex pathology of SCI

    21 AST-OPC1 – Addressing the complex pathology of SCI AST-OPC1 is a cellular therapy with embryonic-derived oligodendrocyte progenitor cells (OPCs) OPCs, which function to support and myelinate neurons, can be damaged and lost in SCIReplacement of lost OPCs could result in:Remyelination of axonsPrev

  22. Slide 22: AST-OPC1 reduced cavity formation and improved motor function in rat model

    AST-OPC1 reduced SCI cavity formation, induced myelination and improved motor function in a rat SCI model Brown: antibody to human nuclear antigen labels AST-OPC1; Blue: Eriochrome Cyanine stains myelin 9 months post-transplant with AST-OPC1 hNucEC 1 mm 100 µm AST-OPC1 in SCI Lesion; Significantly R

  23. Slide 23: AST-OPC1 well tolerated in Phase 1 study

    23 AST-OPC1 was well tolerated, did not illicit an immune response and showed signs on MRI consistent with activity in PI study AST-OPC1 well tolerated, with no SAEs to date deemed related to the cells, delivery method, or immunosuppressive regimen Well Tolerated Activity No evidence of immune respo

  24. Slide 24: Phase 1/2a trial evaluating escalating doses of cells

    24 Phase 1/2a trial evaluating 3 escalating doses of cells (in progress) Cohort 13 subjects2M cells Cohort 25 subjects10M cells Cohort 35 subjects20M cells Expansion cohort1Up to 27 patients10M and/or 20M cells Q3 2015Cohort 1 completedContinued strong safety dataFirst patient has converted from AIS

  25. Slide 25: Target Product Profile for AST-OPC1 in Complete Cervical SCI

    25 Target Product Profile for AST-OPC1 in Complete Cervical SCI: Increase of ≥20% in the patients regaining two or more motor levels of function Would translate into clinically significant improvements in ability to self-care, significant reductions in cost of care Steeves et al., Top Spinal Cord In

  26. Slide 26: OPC1: Addressing the devastating effects and high cost of SCI

    OPC1: Addressing the devastating effects and high cost burden of spinal cord injury (SCI) Spinal cord injury (SCI) affects 12,500 patients per year in U.S.1Primarily affects young and previously healthy males in their 20s and 30s at time of injury and there are no currently approved therapiesThe dir

  27. Slide 27: Financial Snapshot and Listing Details

    27 Based on share price of $4.69 as of March 30, 2016As of December 31, 2015, per Q4 2016 earnings release. Financial Snapshot Listing DetailsExchange: NYSE MKT / ASTShares outstanding (weighted average): 37.8m2Market capitalization: $180m1Financials$11.2m in cash2 $17m in marketable securities2 Rec

  28. Slide 28: Clinical-Stage Programs and Corporate Highlights

    28 Technology Platforms Non-Dilutive Funding via Partnerships AST-VAC1 – Planning P3 trial in acute myeloid leukemia (AML)AST-VAC2 – Planning P1/2a trial in non-small cell lung cancer (NSCLC)AST-OPC1 – Ongoing Phase 1/2a trial in spinal cord injury (SCI) California Institute of Regenerative Medicine

Asterias Biotherapeutics — Investor Presentation (April 2016) on 6ix